MolVerity AI helps discovery organizations screen, prioritize and de-risk candidate molecules using reliability-centered computational evidence — starting with ToxVerity and expanding toward configurable validated endpoint panels.
Surface which compounds warrant early laboratory time and which need further evidence first.
Complement medicinal chemistry and toxicology workflows with transparent computational evidence.
Generate structured computational toxicity outputs for client programs.
Use transparent research-grade predictions for experimental prioritization.
Screening programs can be configured around the available validated endpoints most relevant to a customer’s discovery program, therapeutic area, chemical space, development stage and internal risk priorities.
Ames, hERG, SR-ARE, SR-ATAD5, SR-MMP and SR-p53.
A future customer panel might combine hERG, genotoxicity, CYP inhibition, solubility, permeability, BBB penetration, metabolic stability or clearance — but only where those endpoint models have become available and validated.
Your candidate molecular library.
Endpoint-specific screening runs.
Calibrated toxicity calls.
Uncertainty, domain, novelty and OOD.
Structured testing priority.
Laboratory confirmation on prioritized compounds.
Discuss a research pilot using your candidate compounds. Pricing is not published at this stage.
